Is Lurbinectedin Approved for Ovarian Cancer?
No, lurbinectedin (brand name Zepzelca) is not a standard first-line or maintenance treatment for ovarian cancer. The FDA approved it in 2020 solely for metastatic small cell lung cancer (SCLC) in adults after platinum-based chemotherapy.[1] No regulatory approvals exist for ovarian cancer from FDA, EMA, or major agencies.
Has It Shown Promise in Ovarian Cancer Trials?
Lurbinectedin has been tested in ovarian cancer, mainly platinum-resistant cases. Phase II trials (e.g., NCT02454972) reported response rates of 25-30% in heavily pretreated patients, with median progression-free survival around 4 months.[2] It's active as monotherapy or combined with drugs like doxorubicin or gemcitabine, but these are investigational. No phase III trials confirm superiority over standards like bevacizumab, PARP inhibitors, or platinum rechallenge.
Why Isn't It Standard of Care?
Standard ovarian cancer treatments follow NCCN guidelines: surgery, platinum-taxane chemo for first-line; PARP inhibitors (e.g., olaparib) for BRCA-mutated maintenance; bevacizumab or mirvetuximab soravtansine for later lines.[3] Lurbinectedin lacks level 1 evidence (randomized phase III data) in ovarian cancer, so it's not guideline-recommended. Ongoing trials like CORAIL (NCT05331083) explore combos with atezolizumab, but results are pending.
When Might It Become an Option?
Lurbinectedin could gain traction if trials succeed. A phase III study (NCT04799275) tests it with pegylated liposomal doxorubicin vs. doxorubicin alone in platinum-resistant disease, with data expected 2025-2026. Patent protection lasts until around 2031, potentially delaying generics.[4] Access now is via clinical trials or compassionate use.
Common Side Effects in Ovarian Cancer Studies
Patients report myelosuppression (neutropenia in 50-70%), fatigue, nausea, and transaminitis. Liver monitoring is required, and it's contraindicated in severe hepatic impairment.[2]
Sources
[1]: FDA Approval Summary for Zepzelca
[2]: Trigo et al., Lancet Oncol 2020 (Phase II ovarian data)
[3]: NCCN Ovarian Cancer Guidelines v2.2024
[4]: DrugPatentWatch: Lurbinectedin Patents